Novo Nordisk Price to Sales Ratio 2010-2023 | NVO

Historical PS ratio values for Novo Nordisk (NVO) over the last 10 years. The current P/S ratio for Novo Nordisk as of April 18, 2024 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Novo Nordisk P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2024-04-18 122.75 16.38
2023-12-31 102.71 $7.50 13.70
2023-09-30 90.29 $6.84 13.20
2023-06-30 79.95 $6.29 12.71
2023-03-31 78.62 $5.82 13.50
2022-12-31 66.35 $5.22 12.71
2022-09-30 48.84 $5.04 9.69
2022-06-30 54.34 $4.91 11.06
2022-03-31 54.15 $4.78 11.34
2021-12-31 54.10 $4.86 11.13
2021-09-30 46.37 $4.68 9.92
2021-06-30 40.25 $4.49 8.97
2021-03-31 32.39 $4.27 7.59
2020-12-31 33.11 $4.15 7.98
2020-09-30 32.91 $4.06 8.11
2020-06-30 30.79 $3.97 7.76
2020-03-31 28.31 $3.97 7.13
2019-12-31 26.85 $3.84 6.99
2019-09-30 23.98 $3.64 6.59
2019-06-30 23.47 $3.59 6.55
2019-03-31 24.06 $3.54 6.80
2018-12-31 21.19 $3.52 6.02
2018-09-30 21.68 $3.60 6.01
2018-06-30 21.01 $3.56 5.90
2018-03-31 22.43 $3.51 6.39
2017-12-31 24.04 $3.42 7.04
2017-09-30 21.57 $3.37 6.41
2017-06-30 19.02 $3.33 5.71
2017-03-31 15.20 $3.30 4.61
2016-12-31 15.58 $3.27 4.76
2016-09-30 18.07 $3.25 5.57
2016-06-30 23.15 $3.21 7.22
2016-03-31 23.32 $3.16 7.37
2015-12-31 24.57 $3.11 7.91
2015-09-30 22.94 $3.08 7.46
2015-06-30 23.16 $3.06 7.58
2015-03-31 22.58 $3.03 7.44
2014-12-31 17.63 $3.00 5.87
2014-09-30 19.84 $2.95 6.73
2014-06-30 19.25 $2.87 6.70
2014-03-31 19.02 $2.81 6.77
2013-12-31 15.11 $2.76 5.48
2013-09-30 13.84 $2.68 5.16
2013-06-30 12.67 $2.61 4.85
2013-03-31 13.21 $2.53 5.22
2012-12-31 13.09 $2.45 5.34
2012-09-30 12.66 $2.33 5.42
2012-06-30 11.66 $2.26 5.15
2011-12-31 9.08 $2.15 4.22
2011-09-30 7.84 $2.10 3.74
2011-06-30 9.87 $2.05 4.81
2011-03-31 9.87 $1.98 5.00
2010-12-31 8.74 $2.03 4.30
2010-09-30 7.65 $1.93 3.96
2010-06-30 6.29 $1.87 3.37
2012-03-31 11.12 $1.82 6.12
2010-03-31 5.99 $1.66 3.62
2009-12-31 4.87 $1.60 3.04
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $550.845B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $708.775B 118.03
Johnson & Johnson (JNJ) United States $351.202B 13.93
Merck (MRK) United States $317.211B 83.49
AbbVie (ABBV) United States $291.555B 14.82
AstraZeneca (AZN) United Kingdom $211.944B 18.78
Novartis AG (NVS) Switzerland $196.211B 13.59
Pfizer (PFE) United States $143.772B 13.87
Sanofi (SNY) $114.819B 10.34
Innoviva (INVA) United States $0.929B 6.56